HealthEquity director Adrian Dillon sells $798k in shares

HealthEquity director Adrian Dillon divested 7,632 shares of the company's common stock, amounting to $798,372, in a transaction recorded on August 25, 2026, as per a recent SEC filing. The sale comprised two portions: 6,300 shares exchanged at prices between $104.10 and $105.07, and an additional 1,332 shares at prices between $105.10 and $105.53.

This move followed the purchase of the same amount of shares via the exercise of stock options, purchased at $32.50 per share, for a total cost of $248,040. The stock has yielded a 22% return over the last six months, currently trading at $93.39. These transactions were executed in accordance with a Rule 10b5-1 trading plan that Dillon initiated on December 20, 2025.

Post the sale, Dillon owns 62,395 shares of HealthEquity. According to InvestingPro analysis, the stock appears undervalued at present, given the company's strong financial health. Meanwhile, HealthEquity reported a positive earnings beat in its second-quarter fiscal 2027 financials, reporting non-GAAP earnings of $1.24 per share, beating the estimated $1.19 per share.

The company also delivered revenue of $350.73 million, slightly exceeding the forecasted $349.22 million, marking an 8% increase annually. Despite these favorable results, the stock price dipped, mirroring investor apprehension regarding the company's future outlook. HealthEquity has adjusted its full-year earnings guidance, indicating confidence in its ongoing performance.

The earnings increase was by 4.2%, while revenue outpaced expectations by 0.43%. This indicates the company's capacity to outperform expectations, even as market reactions suggest a focus on future challenges.